A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors

Conditions: Breast Neoplasms; Gastroesophageal Junction Adenocarcinoma; HER2 Low Breast Neoplasms; HER2 Positive Breast Neoplasms; Stomach Neoplasms; Triple Negative Breast Neoplasms Interventions: Drug: disitamab vedotin; Drug: tucatinib Sponsors: Seagen Inc.; RemeGen Co., Ltd. Not yet recruiting

https://clinicaltrials.gov/study/NCT06157892

Source: ClinicalTrials.gov - December 6, 2023 Category: Research Source Type: clinical trials